戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ine methylbromide (a peripherally restricted muscarinic antagonist).
2 ong-acting beta(2)-agonists plus long-acting muscarinic antagonists).
3 f pilocarpine were blocked by scopolamine, a muscarinic antagonist.
4 in 23 minutes after topical application of a muscarinic antagonist.
5 locked by a specific alpha2-antagonist and a muscarinic antagonist.
6 s reversed by administration of nicotinic or muscarinic antagonists.
7  was discovered as a very promising class of muscarinic antagonists.
8 ted side effects requiring co-treatment with muscarinic antagonists.
9 n preceded by HVc injections of nicotinic or muscarinic antagonists.
10 and facilitating synapses was blocked by the muscarinic antagonist, 1-5 microM atropine.
11 y an intrastriatal infusion of a cholinergic muscarinic antagonist, a manipulation that greatly suppr
12 1895 (59) mug, with 12 receiving long-acting muscarinic antagonist and 13 leukotriene receptor antago
13                                    The MABA (muscarinic antagonist and beta(2) agonist) concept has t
14 ibe the subsequent lead optimization of both muscarinic antagonist and beta2 agonist activities, thro
15 e strongly attenuated by local infusion of a muscarinic antagonist and weakly attenuated by a nicotin
16 edding two distinct pharmacophores acting as muscarinic antagonists and beta(2) agonists (MABAs) prom
17 t cholinergic agonists promote REM sleep and muscarinic antagonists and monoamines inhibit REM sleep.
18 l longer acting inhaled beta(2)-agonists and muscarinic antagonists (and combinations) are now in dev
19 roid, long-acting beta2 agonist, long-acting muscarinic antagonist, and leukotriene receptor antagoni
20  recommend inhaled beta-adrenergic agonists, muscarinic antagonists, and, for frequent exacerbators,
21                           Add-on long-acting muscarinic antagonists are recommended in individuals wh
22 esence of TTX but were mostly blocked by the muscarinic antagonist atropine (ATR), and the remainder
23                                          The muscarinic antagonist atropine and the muscarinic recept
24 ntagonists would worsen pathophysiology, the muscarinic antagonist atropine reduced IIS frequency.
25 uld be blocked by topical application of the muscarinic antagonist atropine to the eye, indicating th
26 e global rise in Ca(2+) was inhibited by the muscarinic antagonist atropine.
27 tinic antagonist mecamylamine but not by the muscarinic antagonist atropine.
28 ecovery in these animals is inhibited by the muscarinic antagonist atropine.
29 mulation is performed in the presence of the muscarinic antagonist atropine.
30                                          The muscarinic antagonists atropine, scopolamine, and tropic
31                                    Second, a muscarinic antagonist (atropine) completely abolished st
32 in intracellular Ca(2+) was inhibited by the muscarinic antagonist, atropine.
33             Both actions were blocked by the muscarinic antagonist, atropine.
34 ntly reduced by pretreatment with the i.c.v. muscarinic antagonist, atropine.
35                                  Atropine, a muscarinic antagonist, blocked the effects of ACh on Ip
36  antagonized by atropine (a centrally active muscarinic antagonist) but not by scopolamine methylbrom
37 rsus a long-acting beta2-agonist/long-acting muscarinic antagonist combination for exacerbation preve
38     However, the addition of the long-acting muscarinic antagonist component to BDP/FF reduced this s
39 -level acoustic stimulation and suggest that muscarinic antagonists could enhance the resistance of t
40                                          All muscarinic antagonists currently used as bronchodilating
41        This was tested with the M3-selective muscarinic antagonist darifenacin.
42                       Finally, we designed a muscarinic antagonist DART in one iteration, demonstrati
43  PI hydrolysis and the effect was blocked by muscarinic antagonists, demonstrating mediation by musca
44 ice were treated with i-Extract, followed by muscarinic antagonist (dicyclomine) and agonist (pilocar
45                                         Each muscarinic antagonist displaced [N-methyl-3H]scopolamine
46 MT-7, a highly selective and irreversible m1 muscarinic antagonist, drastically attenuated this respo
47 er controller approaches include long-acting muscarinic antagonists (eg, tiotropium), and biological
48  combined administration of serotonergic and muscarinic antagonists eliminates hippocampal theta acti
49 iperazine lead structure 2, from a family of muscarinic antagonists, gave compound 8 which has improv
50 eta2-agonist (indacaterol) and a long-acting muscarinic antagonist (glycopyrrolate), compared with it
51 cts of vagal stimulation were blocked by the muscarinic antagonist glycopyrronium (5 mg kg(-1)).
52 st formoterol fumarate (FF), and long-acting muscarinic antagonist glycopyrronium (G) is in developme
53 owever, the neural and behavioral effects of muscarinic antagonists have yet to be explored in non-hu
54 = 0.48, 95% CI = 0.43-0.52) and short-acting muscarinic antagonists (HR = 0.43, 95% CI = 0.37-0.49) f
55 ) as being the most selective synthetic M(4) muscarinic antagonist identified to date.
56            There is concern that long-acting muscarinic antagonists increase cardiovascular morbidity
57 -daily long-acting beta2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrronium 110/50
58 eep-induction can be completely blocked by a muscarinic antagonist, indicating that the REM sleep-ind
59 as long-acting beta(2)-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phospho
60 pium and ipratropium, a structurally similar muscarinic antagonist, inhibited capsaicin responses in
61                                  Neither the muscarinic antagonist ipratropium nor the phospholipase
62 -amplitude GI contractions with nonselective muscarinic antagonists is limited in efficacy due to typ
63 ors (long-acting beta2-agonists /long-acting muscarinic antagonist, LABA/LAMA) represented the least
64 s an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatme
65 ng-acting beta(2)-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LA
66                  Tiotropium is a long acting muscarinic antagonist (LAMA), licensed as triple therapy
67 one and mucus secretion, inhaled long-acting muscarinic antagonists (LAMA) are a pillar for the treat
68                                  Long-acting muscarinic antagonists (LAMA) are used for long-term tre
69 agonist [LTRA], theophylline, or long-acting muscarinic antagonist [LAMA]) steadily increased over ti
70 D) recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long-acting beta-agon
71                                  Long-acting muscarinic antagonists (LAMAs) have demonstrated efficac
72 -adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reduction
73 The benefits and harms of adding long-acting muscarinic antagonists (LAMAs) to inhaled corticosteroid
74                                  Long-acting muscarinic antagonists (LAMAs), such as tiotropium, are
75         Recent work in rodents suggests that muscarinic antagonists may enhance myelination with beha
76 pes, Oxo-M could be antagonized by 10 microM muscarinic antagonists methoctramine and tropicamide but
77                                   Longacting muscarinic antagonists might also provide additive benef
78 nity has not been reported for any synthetic muscarinic antagonist, nor for natural occurring M(4) an
79 sociation of the initiation of a long-acting muscarinic antagonist or long-acting beta agonist with t
80 9% and 55% receiving concomitant long-acting muscarinic antagonists or long-acting beta(2)-agonists,
81                       Simultaneous atropine (muscarinic antagonist) or PD142893 (endothelin antagonis
82 ong-acting beta(2)-agonists plus long-acting muscarinic antagonists) or triple inhaled therapy (inhal
83 by pertussis toxin, atropine (a nonselective muscarinic antagonist), or methoctramine (a selective M2
84 d glucocorticoid), tiotropium (a long-acting muscarinic antagonist), or placebo.
85   Therefore, solifenacin and other selective muscarinic antagonists represent new adjunct approaches
86                                          The muscarinic antagonist scopolamine (10(-6) M) had no sign
87 ycaconitine citrate hydrate (MLA) (20 mM) or muscarinic antagonist scopolamine (40 mM) together with
88               Systemic administration of the muscarinic antagonist scopolamine (50 mg/kg) partially a
89 strated that intra-accumbens infusion of the muscarinic antagonist scopolamine 3 hr before the testin
90 ampal injections (30 microg per side) of the muscarinic antagonist Scopolamine augmented adrenocortic
91                        Pretreatment with the muscarinic antagonist scopolamine hydrobromide (1.5-6 mg
92                    Furthermore, applying the muscarinic antagonist scopolamine reduced attentional mo
93  selective GluN2B antagonist, CP-101,606 and muscarinic antagonist scopolamine which have both been s
94 he serotonergic antagonist methiothepin, the muscarinic antagonist scopolamine, both drugs, or saline
95 levels and the increases were blocked by the muscarinic antagonist scopolamine.
96 e blunted by preinjury administration of the muscarinic antagonist, scopolamine.
97          Here, we tested the hypothesis that muscarinic antagonists selectively disrupt coupling betw
98 , long-acting beta2-agonist, and long-acting muscarinic antagonist, several of which are now in devel
99     They were prevented by the M1-preferring muscarinic antagonists, telenzepine, pirenzepine, and tr
100 ve activity was reversed completely by every muscarinic antagonist tested, which indicates that they
101  (ICS) (n = 1097), 5 RCTs of the long-acting muscarinic antagonist tiotropium (n = 4592), and 6 RCTs
102                      The long acting inhaled muscarinic antagonist tiotropium (Spiriva) improves lung
103 rm the overall utility of adding long-acting muscarinic antagonist to ICS/long-acting B(2)-agonist in
104 controlled asthma, addition of a long-acting muscarinic antagonist to inhaled corticosteroid plus lon
105 cting bronchodilators, including long-acting muscarinic antagonists, to reduce hyperinflation.
106 is setting occupancy of the receptors with a muscarinic antagonist was without detectable effect on a
107 e odds ratio for prescription of long-acting muscarinic antagonists was 2.27 (95% CI = 1.38-3.70).
108 nic antagonists - and atropine (2 mg/kg) - a muscarinic antagonist - were ineffective against psychos
109 agonist), and glycopyrronium (G; long-acting muscarinic antagonist) with the combination of BDP with
110 le-blinded study of trihexyphenidyl (THP), a muscarinic antagonist, with an incentivised eye movement

 
Page Top